Strengths

Zimmer Biomet’s global scale in orthopedics supports broad surgeon and hospital access, but peers like Stryker and J&J’s DePuy often show stronger innovation-led pull.

Its focused implant portfolio in hips, knees, and extremities creates category depth, which helps defend share against diversified medtech peers with broader but less concentrated exposure.

A 5.5% TTM ROIC indicates the franchise still generates positive returns on capital, although it trails higher-quality peers that convert scale into stronger economic profit.

The company’s installed commercial relationships and procedure-based demand provide recurring replacement and revision activity, which is structurally steadier than many discretionary medtech peers.

Weaknesses

A 25.7-day cash conversion cycle is now much shorter than last month’s 348-day figure, but the business still remains working-capital intensive relative to more efficient peers.

Net debt to EBITDA of 3.6x leaves leverage elevated for a cyclical implant business, reducing resilience versus peers with cleaner balance sheets.

A quick ratio of 1.69 suggests better near-term liquidity headroom than previously assumed, though balance-sheet flexibility is still not peer-leading.

The low ROIC versus the cost of capital indicates that operational execution has not yet translated into peer-leading value creation, limiting structural positioning.

Opportunities

Revision procedures and aging-population demand can support long-run orthopedic volumes, and Zimmer Biomet is positioned to benefit alongside peers in mature joint-replacement markets.

Digital surgery, robotics, and data-enabled workflow tools can improve surgeon loyalty and procedure efficiency, narrowing the gap with more advanced peers if adoption accelerates.

Portfolio simplification and supply-chain improvement could reduce working-capital drag, allowing Zimmer Biomet to close the efficiency gap with stronger operators.

Emerging-market orthopedic penetration remains lower than in developed markets, giving the company room to expand where peer competition is still less entrenched.

Threats

Stryker, J&J, and other large peers continue to outspend Zimmer Biomet on innovation and commercial execution, threatening share in premium implant categories.

Pricing pressure from hospitals and group purchasing organizations can compress margins across orthopedics, and Zimmer Biomet’s weaker efficiency leaves less buffer than top peers.

Procedure timing remains sensitive to elective-surgery cycles, so macro slowdowns can delay volumes and expose the company more than diversified medtech peers.

High leverage and long cash conversion increase vulnerability if growth disappoints, because peers with stronger balance sheets can absorb shocks more easily.

Overall Score

Zimmer Biomet remains a meaningful orthopedic franchise, but weaker capital efficiency, leverage, and working-capital intensity leave it structurally behind the strongest peers.